Subscribe
shutterstock_1425438833_ii-studio
II.studio / Shutterstock.com
28 April 2020AmericasRory O'Neill

Argentum can't bring Gilenya patent challenge

Argentum Pharmaceuticals can’t have a  Novartis patent for a multiple sclerosis drug invalidated because it doesn’t have standing to bring the challenge, the US Court of Appeals for the Federal Circuit has ruled.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pfizer fails to establish standing for patent challenge
28 April 2020   Pfizer has been rebuked by judges for filing thin evidence in support of what the pharma company called its ‘self-evident’ standing to bring a patent challenge.
Americas
Novartis tries to block generic versions of Gilenya, enforces new patent
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
Pfizer fails to establish standing for patent challenge
28 April 2020   Pfizer has been rebuked by judges for filing thin evidence in support of what the pharma company called its ‘self-evident’ standing to bring a patent challenge.
Americas
Novartis tries to block generic versions of Gilenya, enforces new patent
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

More on this story

Americas
Pfizer fails to establish standing for patent challenge
28 April 2020   Pfizer has been rebuked by judges for filing thin evidence in support of what the pharma company called its ‘self-evident’ standing to bring a patent challenge.
Americas
Novartis tries to block generic versions of Gilenya, enforces new patent
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler